These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23426962)

  • 41. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
    Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
    Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions.
    Deftereos G; Finkelstein SD; Jackson SA; Ellsworth EM; Krishnamurti U; Liu Y; Silverman JF; Binkert CR; Ujevich BA; Mohanty A
    Mod Pathol; 2014 Apr; 27(4):594-601. PubMed ID: 24051700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
    Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
    García-Solano J; Conesa-Zamora P; Carbonell P; Trujillo-Santos J; Torres-Moreno D D; Pagán-Gómez I; Rodríguez-Braun E; Pérez-Guillermo M
    Int J Cancer; 2012 Oct; 131(8):1790-9. PubMed ID: 22287190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.
    Siddiqui AA; Kowalski TE; Kedika R; Roy A; Loren DE; Ellsworth E; Adler D; Finkelstein SD
    Gastrointest Endosc; 2013 Apr; 77(4):669-70. PubMed ID: 23498145
    [No Abstract]   [Full Text] [Related]  

  • 49. [Detection of KRAS mutations in tumor cells using biochips].
    Emel'ianova MA; Amosenko FA; Chudinov AV; Surzhikov SA; Kazubskaia TP; Liubchenko LN; Nasedkina TV
    Mol Biol (Mosk); 2011; 45(5):863-70. PubMed ID: 22393783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis.
    Spinelli M; Du Parcq P; Gupta N; Khorashad J; Viola P
    Pathologica; 2022 Jun; 114(3):221-227. PubMed ID: 35775708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.
    Shi C; Fukushima N; Abe T; Bian Y; Hua L; Wendelburg BJ; Yeo CJ; Hruban RH; Goggins MG; Eshleman JR
    Cancer Biol Ther; 2008 Mar; 7(3):353-360. PubMed ID: 18075308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
    Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
    J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
    Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
    Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
    Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
    Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
    Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and epigenetic markers in the evaluation of pancreatic masses.
    Ginestà MM; Mora J; Mayor R; Farré A; Peinado MA; Busquets J; Serrano T; Capellá G; Fabregat J
    J Clin Pathol; 2013 Mar; 66(3):192-7. PubMed ID: 23135349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
    Kim HS; Kim JI; Jeong M; Seo JH; Kim IK; Cheung DY; Kim TJ; Kang CS
    World J Gastroenterol; 2014 Sep; 20(35):12682-6. PubMed ID: 25253976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method.
    Rückert F; Aust D; Böhme I; Werner K; Brandt A; Diamandis EP; Krautz C; Hering S; Saeger HD; Grützmann R; Pilarsky C
    J Surg Res; 2012 Jan; 172(1):29-39. PubMed ID: 21683373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
    Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
    Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.